PY2117301A - Compuestos para su uso en infecciones víricas - Google Patents

Compuestos para su uso en infecciones víricas

Info

Publication number
PY2117301A
PY2117301A PY202102117301A PY2117301A PY2117301A PY 2117301 A PY2117301 A PY 2117301A PY 202102117301 A PY202102117301 A PY 202102117301A PY 2117301 A PY2117301 A PY 2117301A PY 2117301 A PY2117301 A PY 2117301A
Authority
PY
Paraguay
Prior art keywords
compounds
viral infections
virus
treatment
viral infection
Prior art date
Application number
PY202102117301A
Other languages
English (en)
Spanish (es)
Inventor
Losada González Alejandro
María Fernández- Sousa José
Avilés Marín Pablo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PY2117301A publication Critical patent/PY2117301A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PY202102117301A 2020-03-02 2021-03-02 Compuestos para su uso en infecciones víricas PY2117301A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25

Publications (1)

Publication Number Publication Date
PY2117301A true PY2117301A (es) 2022-08-09

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
PY202102117301A PY2117301A (es) 2020-03-02 2021-03-02 Compuestos para su uso en infecciones víricas
PY202102117308A PY2117308A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias

Family Applications After (1)

Application Number Title Priority Date Filing Date
PY202102117308A PY2117308A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias

Country Status (17)

Country Link
US (2) US20230159594A1 (https=)
EP (2) EP4114433A2 (https=)
JP (2) JP2023517536A (https=)
KR (2) KR20220151643A (https=)
CN (2) CN115461067A (https=)
AU (2) AU2021232535A1 (https=)
BR (2) BR112022016604A2 (https=)
CA (2) CA3169540A1 (https=)
CL (2) CL2022002396A1 (https=)
CO (2) CO2022014093A2 (https=)
IL (2) IL296069A (https=)
MX (2) MX2022010926A (https=)
PE (2) PE20230606A1 (https=)
PY (2) PY2117301A (https=)
TW (2) TWI908772B (https=)
UY (2) UY39109A (https=)
WO (2) WO2021175831A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158102A1 (en) * 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in the treatment of coronavirus infection
CN115461067A (zh) * 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物
AU2021231521A1 (en) * 2020-03-02 2022-10-06 Pharma Mar, S.A. PLD for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO1999052515A2 (de) * 1998-04-14 1999-10-21 Hassan Jomaa Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
DK1347743T3 (da) * 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
EP1596823A2 (en) * 2003-02-21 2005-11-23 Sun Pharmaceuticals Industries Ltd. A stable ophthalmic composition
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー,マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
BR112012014624A8 (pt) * 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CN115461067A (zh) * 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物

Also Published As

Publication number Publication date
WO2021175857A1 (en) 2021-09-10
JP2023517536A (ja) 2023-04-26
IL296068A (en) 2022-11-01
PE20230412A1 (es) 2023-03-07
PY2117308A (es) 2022-08-09
TWI908772B (zh) 2025-12-21
TW202144381A (zh) 2021-12-01
CN115461067A (zh) 2022-12-09
KR20220150350A (ko) 2022-11-10
JP2023517535A (ja) 2023-04-26
UY39109A (es) 2021-09-30
CA3169540A1 (en) 2021-09-10
US20230159594A1 (en) 2023-05-25
UY39110A (es) 2021-09-30
AU2021232535A1 (en) 2022-10-06
CL2022002395A1 (es) 2023-06-30
BR112022016604A2 (pt) 2022-10-11
MX2022010921A (es) 2022-09-29
KR20220151643A (ko) 2022-11-15
AU2021231197A1 (en) 2022-10-06
EP4114435A1 (en) 2023-01-11
IL296069A (en) 2022-11-01
CO2022014093A2 (es) 2022-11-18
TW202146038A (zh) 2021-12-16
EP4114433A2 (en) 2023-01-11
US20230295236A1 (en) 2023-09-21
WO2021175831A3 (en) 2021-10-14
PE20230606A1 (es) 2023-04-10
CA3169544A1 (en) 2021-09-10
WO2021175831A2 (en) 2021-09-10
CN115666616A (zh) 2023-01-31
CL2022002396A1 (es) 2023-06-30
CO2022014031A2 (es) 2022-10-21
MX2022010926A (es) 2022-09-29
BR112022016675A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
CO2022014031A2 (es) Compuestos para su uso en infecciones víricas
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
CL2018001207A1 (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
ECSP14013315A (es) Inhibidores de aplicación viral
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
DOP2013000185A (es) Compuestos antivirales
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
MX381896B (es) Compuestos de tiazolida para el tratamiento de infecciones virales.
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CU20200009A7 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
CO2019011305A2 (es) Tratamiento de una infección vaginal bacteriana
MX2022008062A (es) Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d.
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.